- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02845583
Nursing Activities for High Complexity Oncologic Care Patients
Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients
Study Overview
Status
Conditions
Detailed Description
Study design
The methodological approach used to achieve the objective of this research is quantitative. A mixed study design is being adopted:
- Retrospective study to determine the nature and volume of activity provided at nursing classes of patients whose admission is attributed to a specific DRG
- Longitudinal prospective study to determine the variability of costs of nurses with regard to DRG refund, comparatively to distribution of patients for every single section (high, medium, low complexity).
Study population The sample has been chosen considering the prevalence of hospitalizations per year in medical oncology U.O.C. related to certain DRG and characterized by greater complexity of care, so as to provide a useful information base for study. For the retrospective study the survey will be conducted on a sample of 150 patients. Patients will be enrolled at high, medium and low complexity of care, hospitalized for chemotherapy and for biliary obstructive urinary tract and in the first half of 2016. It is estimated that the sample represents 30% of the total number of admissions made in 2016. A prospective longitudinal study will take into consideration a sample of 150 patients with the same characteristics considered for enrollment in the retrospective study.
The study will include patients who under go: CHT with a duration of hospital stay of 2-3 days (microcitomi and NHL), CHT with a length of hospital stay of 4-5 days (sarcomas), CHT with a length of hospital stay > 5 days or at high doses (testicle cancer, Ewing's sarcoma and bone sarcoma) and patients with higher complexity care.
Patients of 18 years of age or less will be excluded, as well as patients that were transferred to other units while inpatient, patients transferred in U.O.C. of Oncology after major surgery procedures in other departments, and admissions that are outliers.
The duration for the monitoring phase on the allocation and the distribution of patients among the different sections of hospital care intensity (Intensità di cure, IC) and care complexity (Complessità Assistenziale, CA), based on the results obtained by the Triage of corridor (TriCO), is estimated for 3 months up to a maximum of six months starting from March 2016. For the collection of data relating to the amount and types of activities provided in the first half of 2016 is estimated to have a maximum of 30 days and others 30 days for the detection the relative DRG reimbursed for hospitalizations considered.
Survey instruments
- Professional Assessment Instrument (PAI). It is a tool that documents nursing processes implemented in a computerized way using nursing language according to the North American Nursing Diagnosis Association International (NANDA-I).
- Hospital discharge card (Scheda di dimissione ospedaliera, SDO). It is a tool that contains information about each patient discharged, that are necessary for the attribution to DRG and for finding the rate payable for each episode of hospitalization
- Scheda di mobilità interna dei pazienti. It is a card that contains data of Tri-CO at the entrance of the patient and any variations of that index during hospitalization.
Interventions The study will be presented to the manager and coordinator of the U.O.C. Medical Oncology through a moment of training/information.
In order to collect data on the variation of Tri-CO during hospitalization, and consequently the different allocation to U.O.C. of Oncology of patients in sections of low, medium and high complexity of care, a point of contact (nurse) will be identified who will deal with the collection and retention of such information in the manner set out in the research protocol.
Outcome measures
The primary outcome expected by the survey is the quantification of the volume of nursing activities provided to patients and its cost. In addition, we expect to realize economic indicators which make it possible to ascertain:
- Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care of the patient;
- Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge.
- Gap between theoretical and actual cost of nurses in relation to the care delivered for a specific patient; Knowledge of actual costs for each distinct and specific episode of hospitalization would enhance its "uniqueness". An economic analysis of labor nursing costs for individual patient could provide input for the determination of the costs of all the professionals of the Foundation, contributing to the improvement of corporate strategic management for resource allocation.
Statistical analysis Statistical analyses will be performed using methods of descriptive statistics and inferential statistics appropriate to the sample size and study variables. Prospective longitudinal study will be used to determine the frequency distribution and the variance on the stay of the patients in each individual section of hospital in-patient treatment which is attributed to a specific DRG. Then a factorial analysis and regression techniques will be used to measure the type of bond that exists between the dependent variable Y (nursing) and independent variables X1, X2, X3 ... (DRG, age, days of hospitalization, complications, etc). Then the analysis will continue by studying which variables will affect the distribution of patients for IC and CA level and how it can change this assignment during a single in-patient episode, creating a variability in costs of services paid.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Roma, Italy, 00168
- Recruiting
- Universita Cattolica del Sacro Cuore
-
Contact:
- Amelia Palinuro, PhD Student
- Phone Number: +393468599660
- Email: amelia.stop@hotmail.it
-
Contact:
- Maurizio Zega, PhD
- Phone Number: +390630154796
- Email: maurizio.zega@policlinicogemelli.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- CHT with a duration of hospital stay of 2-3 days (microcitomi and NHL),
- CHT with a length of hospital stay of 4-5 days (sarcomas),
- CHT with a length of hospital stay > 5 days (in case of high doses: testicle cancer, Ewing's sarcoma and bone sarcoma)
- Oncologic patients with higher complexity care.
Exclusion Criteria:
- Patients of 18 years of age or less
- Patients transferred to other units while inpatient
- Patients transferred in U.O.C. of Oncology after major surgery procedures in other departments
- Outlier admissions
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Retrospective cohort
150 oncologic patients belonging to major complexity DRGs
|
Perspective cohort
150 oncologic patients belonging to major complexity DRGs
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume of Nursing Activity
Time Frame: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Count of nusing activities performed to patients in different complexity groups
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care (Complessità Assistenziale, CA) of the patient.
Time Frame: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the DRG rate reimbursed in relation to the complexity care of the patient
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge
Time Frame: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Cost weight of the nursing staff on the reimbursement for hospitalization in connection with the DRG of patient discharge.
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Mean difference between theoretical and actual cost of nurses in relation to the care delivered for a specific patient.
Time Frame: Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Difference between theoretical and actual cost of nurses in relation to the care delivered for a specific patient.
The nursing time cost expressed in minutes results from the standard cost for each nursing hour worked by a nurse.
The time in minutes of the performance is detected by the time indicated on standard nursing protocols considered for the study.
The time in minutes of a benefit provided to specific types of patients considered comes from the average execution time of nursing care.
|
Through study completion, based on the patients' discharge date. The first outcome assessments are expected in December 2016.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FAG14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States